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Abstract
Objectives: Metastatic recurrence is the most frequent
cause of death after surgical resection of lung cancer.
Manipulation during surgery has been advocated as one of
the causes contributing to promotion of spreading.
Methods: We investigated if the detection of plasma
circulating free DNA (cfDNA) is influenced by surgical
manipulation in 25 lung cancer patients (17 males and eight
females) undergoing complete resection; 20 health subjects
formed the control group. Bloodstream levels of cfDNA
were detected before surgery, one week and one month
after surgery.
Results: CfDNA levels measured preoperatively and in the
control group were 23 07 ± 7 4 ng/mL and 7 5 ± 3 4 ng/mL
respectively (p=0 0002); levels at one week and one month
were 68 2 ± 36 2 ng/mL and 9 6 ± 3 1 ng/mL respectively.
The difference between the three time points were statisti‐
cally significant (preop vs. one week p=0 0006; one week vs.
one month p=0 0003) with an increase in the first week and
a strong decrease after one month. CfDNA levels at one
month were not statistically different from those recorded
in the control group. There was no correlation between
preoperative cfDNA levels, tumour stage, grading and
histology and patient demographics. No correlation was
found between postoperative cfDNA, type of surgical
procedure, histology and stage. After a median follow-up
of 16 months no recurrence was detected.
Conclusions: Surgical manipulation determines increased
cfDNA levels in the early postoperative period; however,
after one month they decrease within the normal range, at
levels that are statistically comparable with healthy
subjects.
Keywords Lung cancer, circulating free DNA, real-time
quantitative polymerase chain reaction, surgical resection,
recurrence
1. Introduction
Lung cancer is the leading cause of cancer related death
worldwide in both genders [1]. Despite the improved
diagnostic tools and treatment strategy, overall survival is
still poor; metastatic recurrence is also the most important
cause of death after complete resection. The metastatic
process involves a number of steps that unfortunately are
not yet completely understood [2]. In particular, several
authors postulated that manipulation of the tumour during
1J Circ Biomark, 2014, 3:7 | doi: 10.5772/59875
surgery might promote early spreading [3, 4]. Release of
tumour growing factors, surgical stress-related suppres‐
sion of the innate immunity, reduction of anti-angiogenesis
factors and tumour cells shedding in the bloodstream were
considered as possible causes; however, the reported
results were often contradictory due to the heterogeneity
of the study populations.
In 1948 Mandel and Metais demonstrated the presence of
circulating free DNA (cfDNA) in the bloodstream and
subsequent studies showed a correlation between high
cfDNA levels and neoplastic diseases [5–8]. Recently, with
the improvement of extraction and quantification methods,
the determination of cfDNA is becoming a useful diagnos‐
tic and prognostic tool also in lung cancer patients [9, 10].
It has been demonstrated that high preoperative cfDNA
levels show a negative impact on long term survival,
independently from a patient’s age and stage of the disease
[11]. However, the explanation of the mechanism involved
in cfDNA release still remains uncertain. Several hypothe‐
ses (tumour cells lysis, apoptosis, necrosis or active
secretory effects of neoplastic cells) have been proposed,
but none of them is exhaustive [12, 13]. Furthermore, the
relationship between cfDNA levels, disease progression
and metastatic spreading is still debated. Based on previous
experimental studies on cfDNA plasma levels after surgical
procedures, some authors focused on circulating cancer
cells and nucleic acids, postulating in animal models that
their postoperative increased levels might show an impact
on the mechanism of metastatic spreading [14, 15]. How‐
ever, this hypothesis has not yet been confirmed since there
are no clinical studies evaluating the levels of circulating
nucleic acids during the early postoperative course; thus,
we are not able to assess correctly the potential modifica‐
tions during follow-up and understand the role of surgical
manipulation on their release within the bloodstream.
2. Materials and methods
Twenty-five consecutive patients (17 men – eight women;
mean age 62 4 ± 10 years) with lung cancer underwent
complete surgical resection. None of them had a previ‐
ous  history  of  cancer  or  received  induction  therapy.
Twenty voluntary healthy subjects  (10  men –  10  wom‐
en; mean age 37 ± 15 years) were considered as the control
group. After an exhaustive explanation of the objectives
of  the  study,  all  patients  and  controls  signed  an  in‐
formed consent. Fifteen patients (60%) had squamous cell
carcinoma and 10  (40%)  had adenocarcinoma.  None of
them had chronic  viral  infections.  We performed eight
right upper lobectomies, six right lower lobectomies, five
left  upper  lobectomies,  five  left  lower  lobectomies  and
one  right  intrapericardial  pneumonectomy;  in  four
lobectomy patients, because of neoplastic ribs invasion, a
chest  wall  resection  was  required.  In  all  cases  a  com‐
plete  hilar  and mediastinal  lymph node dissection was
performed at the end of the procedure. Interlobar fissures
were created in all cases with surgical staplers, with the
obvious exception of pneumonectomy. No blood transfu‐
sions were required. Fifteen patients (60%) were at stage
I, seven (28%) at stage II and three (12%) at stage IIIA. A
withdrawal  of  6  mL peripheral  blood  was  collected  in
tubes  containing  EDTA  the  day  of  surgery  just  before
induction  of  anaesthesia,  one  week  and  one  month
postoperatively.  The  samples  were  processed  to  obtain
plasma within an hour after the withdrawal of the blood
sample. Plasma was separated from the cellular fraction
by centrifugation two times at 2500 rpm for 10 minutes
at  4°C.  The  resulting  supernatant  (plasma)  was  frozen
at-80°C.  DNA  was  extracted  from  plasma  by  using
QIAamp DNA Mini kit (Qiagen, Italy) according to the
supplier’s instructions; this provided an elution in a final
volume of 50 uL. The DNA was stored at-20°C until  it
was analysed.
To quantify the plasma circulating DNA we used a real-
time quantitative polymerase chain reaction (PCR) ap‐
proach based on the 5’ nucleotide method. This
methodology is based on continuous monitoring of a
progressive fluorogenic PCR by an optical system [16]. The
PCR system uses two amplification primers and an
additional amplicon-specific and fluorogenic hybridiza‐
tion probe, the target sequence of which is located within
the amplicon. The probe is labelled with two fluorescent
dyes. One server was used as a reporter on the 5’ end (FAM
dye; Applied Biosystems, Foster City, CA, USA). The
emission spectrum of the dye is quenched by a second
fluorescent dye at the 3’ end (TAMRA; Applied Biosystems,
Foster City, CA, USA). If amplification occurs, the 5’ to 3’
exonuclease activity of the AmpliTaq (Biosystems, Foster
City, CA, USA) DNA polymerase cleaves the reporter from
the probe during the extension phase, thus releasing it from
the quencher [17]. The resulting increase in fluorescent
emission of the reporter dye is monitored during the PCR
process.
The real-time PCR was performed on an ABI PRISM 7500
Fast Real Time PCR System (Applied Biosystem, Foster
City, CA, USA). Primers and probes were designed to
specifically amplify the ubiquitous gene of interest, the
ACTB2 single copy gene mapped on 5q11.2 (Gene ID:
345651, Applied Biosystem, Foster City, CA, USA). The
amplicon size of the ACTBL2 gene was 67 bp. PCR reaction
was carried out on 96-well plate with 20 uL per well using
1X TaqMan Master Mix. After incubation for two minutes
at 50°C and 10 minutes at 95°C, the reaction continued for
40 cycles at 95°C for 15 seconds and 60°C for one minute.
Each plate consisted of patient samples in triplicates and
multiple water blanks as negative control. For construction
of the calibration curve on each plate, we used a standard
TaqMan Control Human Genomic DNA (Applied Biosys‐
tems, Foster City, CA, USA) with appropriate serial
dilutions at 100, 10, 1, 0 1, 0 01, and 0 001 ng. All of the data
were analysed using the ABI PRISM 7500 software (Ap‐
plied Biosystems Foster City, CA, USA) to interpolate the
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standard amplification curve of DNA at a known quantity
with amplification cycle threshold of the unknown target
sample, obtaining the relative amount of DNA in the
experimental sample.
3. Statistical analysis
Quantitative variables were reported as mean ± standard
deviation and the differences were analysed with the
Student’s T test. Correlation analysis was performed
between cfDNA levels and quantitative variables (age and
tumour dimension). Qualitative variables as stage, patho‐
logical nodal status, histology, presence of tumour ne‐
crosis, grading, type of surgery (standard vs. extended),
and history of smoking were reported as present or absent
and used to identify two groups of patients at the three
different steps. Differences of cfDNA levels between these
groups were assessed by the Student’s T test. Statistical
analysis was performed with SPSS software (version 17 0,
SPSS Inc., USA).
4. Results
The surgical procedure lasted a mean of 88 4 ± 21 3 minutes
(range 62 – 115 minutes). After surgery, all patients were
recovered in the surgical ward. No major postoperative
complications occurred with an uneventful postoperative
course in all patients. No adjuvant therapy has been
administered before the third blood withdrawal at one
month. In all patients the third blood sample was obtained;
furthermore, in 14 patients (56%) we were able to collect
blood samples at six and 12 months. The median follow-up
was 16 months. In the study population and in the control
group the mean preoperative level of cfDNA was 23 07 ± 7
4 ng/ml and 7 5 ± 3 4 ng/ml respectively (p=0 0002). After
one week the cfDNA bloodstream level was 68 2 ± 36 2 ng/
ml (p=0 0006) and after one month the cfDNA values
significantly dropped below preoperative levels (9.6 ± 3.1
ng/ml) (p=0.0001). The difference between the cfDNA
levels measured one month after surgery and those
obtained in healthy subjects did not reach statistical
significance (9 6 ± 3 1 ng/ml vs. 7 5 ± 3 4 ng/ml p=0 1). No
correlation was found between preoperative and one week
cfDNA levels, age (p=0 989 at both time points) and tumour
diameter (p=0 925 and p=0 325 at each time point). No other
variable considered for statistical analysis showed an
impact on cfDNA levels at the different time points of the
study (Table 1); the increase of cfDNA values after one
week seems absolutely independent from any assessed
variable. No statistically significant differences on cfDNA
values were reported between pathological stages neither
preoperatively nor during the follow-up. After a median
follow-up of 16 months no patient showed recurrence;
stage III patients underwent adjuvant chemo-radiothera‐
py. Eighteen patients (72%) were reassessed six months













Smoking (yes/no) 0.98 0.1 0.87
T0: preoperative; T1: 1 week; T2: 1 month; epi: squamous cell carcinoma;
adc: adenocarcinoma
Table 1. P values of cfDNA levels at three steps according to qualitative
variables assessed by independent Student’s T test
Figure 1. Trend of cfDNA levels in patients undergoing surgery
5. Discussion
Metastatic disease is still the leading cause of death after
complete surgical resection of lung cancer. Metastatic
spreading involves several steps: the presence in the
bloodstream of circulating cancer cells (with their nucleic
acids), their passage from blood to distant organs and the
growth in the new site. The mechanism of this process is
not completely understood yet, although it has been
postulated that a reciprocal transition of cancer cells
between the epithelial and mesenchymal status should be
involved [18]. Several authors suggested that surgical
manipulation could promote this cascade already during
the immediate postoperative course; many different
mechanisms have been advocated to elicit this process, in
particular the decrease of immune-competency after
surgery, the production of oxygen free radicals by leuko‐
cytes or tumour cells shedding into the bloodstream [19,
20]. Cell-free tumour nucleic acids (cfDNA) levels have
been proposed as a diagnostic and prognostic tool in
several solid cancers. Furthermore, cfDNA determination
in lung cancer patients has gained importance during
recent years. Yoon and colleagues in 2009 compared cfDNA
levels between lung cancer patients and healthy subjects
finding higher values in the former group [9]. Paci and
colleagues demonstrated that in 151 lung cancer patients
cfDNA levels were higher when compared to healthy
individuals and that the risk of disease increases with
higher cfDNA levels; in particular with a cut-off of 2 ng/ml,
higher concentrations are strongly connected with the
presence of neoplastic disease [10]. Van der Drift and
colleagues in 2010 reported that high cfDNA levels at the
time of diagnosis were a prognostic factor for poor survival,
although no correlation was found with stage, histology
and age [11]. Our study confirms that in the lung cancer
population cfDNA levels are higher than in healthy
subjects. These molecules might not be produced only from
tumour cells degradation; they can also be released by an
active secretory mechanism and they can play a role in the
metastatic process. In fact, it has been demonstrated in an
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animal model that haematogenous dissemination of
tumours due to surgery seems related to the presence of
cfDNA [15]. However, in a study on percutaneous liver
biopsy in patients with hepatocarcinoma no relationship
was found between this procedure and cfDNA plasma
dissemination [21]. Our results show that one week after
surgery, cfDNA levels increase, probably due to manipu‐
lation, but after one month they drop below preoperative
values in all patients and remain stable during the time
period of the study. Thus, since all patients show this
pattern, if surgical manipulation related release should be
involved in the metastatic process, it must be in combina‐
tion with other variables different from patient to patient
(release of tumour growing factors, suppression of innate
immunity, reduction of anti-angiogenesis factors, etc.). The
absence of statistical significance between the study
population one month after surgery and the control group
allows us to conclude that the impact of lung manipulation
is restricted to the very early postoperative course and
cannot influence the metastatic process by itself. The
surgical stress entails an increased inflammatory response
with determination of high cfDNA levels, but probably the
causes and mechanisms of the metastatic process should be
researched somewhere else.
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